The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Autonomic nerve invasion may be simple method of identifying which patients with intermediate-risk T3a prostate cancer who have negative surgical margins after radical prostatectomy are at increased ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

The NanoKnife system employs non-thermal IRE ablation to destroy tumour cells while preserving surrounding anatomy.

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...